上海科创中心建设成果：国产阿兹海默症新药GV-971 - 2019年05月14日

The first drug to treat Alzheimer’s disease, the world’s largest photon scientific infrastructure cluster and a comprehensive, state-level laboratory are among scientific breakthroughs made in Shanghai.
Shanghai-developed drug GV-971, set to hit the market this year, is expected to benefit about 400,000 patients with Alzheimer’s disease, said Peng Song, executive deputy director of the office to promote Shanghai's development as a scientific and technological innovation center.
According to the World Alzheimer’s Report 2018, there are globally about 47 million patients with Alzheimer’s disease. It is an irreversible, progressive brain disorder, and currently there is no cure. But GV-971 offers hope.